Accelerate Your IBD Research with Our Anti-CD40-Induced Colitis Model

Discover how Ace Therapeutics' Anti-CD40-induced colitis model enables rapid and reproducible evaluation of therapeutic strategies in inflammatory bowel disease (IBD). This model offers a powerful platform for understanding innate immune mechanisms and assessing candidate therapies targeting key inflammatory cytokines.

Why This Model Matters

Our acute colitis model, established in RAG-/- mice via intraperitoneal administration of anti-CD40 antibodies, mirrors critical immunopathological features of IBD:

• Rapid onset of disease with measurable symptoms, including weight loss, diarrhea, and rectal bleeding.
• Clear histopathological evidence of mucosal inflammation and crypt destruction.
• Robust cytokine response involving TNF-α, IFN-γ, and IL-12/IL-23 p40, driving acute intestinal inflammation.

These characteristics make it ideal for:

• Mechanistic studies focused on innate immune activation.
• Efficacy evaluations of novel inhibitors targeting TNF-α, IFN-γ, or IL-12/IL-23 pathways.

What You'll Learn in This Case Study

Download the full case study to explore:

• The complete modeling process and dosing protocol (200 µg anti-CD40, i.p.).
• Detailed endpoint readouts—body weight, DAI score, colon length, and colon weight.

Download the case study to see how our Anti-CD40-induced colitis model can streamline your IBD research and therapeutic development.

You might be interested in...